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Abstract 
Background: The malaria vaccine candidate RTS,S/AS01 (GSK Vaccines) induces high IgG concentration against the 
circumsporozoite protein (CSP) of Plasmodium falciparum. In human vaccine recipients circulating anti‑CSP antibody 
concentrations are associated with protection against infection but appear not to be the correlate of protection. How‑
ever, in a humanized mouse model of malaria infection prophylactic administration of a human monoclonal antibody 
(MAL1C), derived from a RTS,S/AS01‑immunized volunteer, directed against the CSP repeat region, conveyed full 
protection in a dose‑dependent manner suggesting that antibodies alone are able to prevent P. falciparum infection 
when present in sufficiently high concentrations. A competition ELISA was developed to measure the presence of 
MAL1C‑like antibodies in polyclonal sera from RTS,S/AS01 vaccine recipients and study their possible contribution to 
protection against infection.
Results: MAL1C‑like antibodies present in polyclonal vaccine‑induced sera were evaluated for their ability to 
compete with biotinylated monoclonal antibody MAL1C for binding sites on the capture antigen consisting of the 
recombinant protein encompassing 32 NANP repeats of CSP (R32LR). Serum samples were taken at different time 
points from participants in two RTS,S/AS01 vaccine studies (NCT01366534 and NCT01857869). Vaccine‑induced 
protection status of the study participants was determined based on the outcome of experimental challenge with 
infected mosquito bites after vaccination. Optimal conditions were established to reliably detect MAL1C‑like antibod‑
ies in polyclonal sera. Polyclonal anti‑CSP antibodies and MAL1C‑like antibody content were measured in 276 serum 
samples from RTS,S/AS01 vaccine recipients using the standard ELISA and MAL‑1C competition ELISA, respectively. A 
strong correlation was observed between the results from these assays. However, no correlation was found between 
the results of either assay and protection against infection.
Conclusions: The competition ELISA to measure MAL1C‑like antibodies in polyclonal sera from RTS,S/AS01 vaccine 
recipients was robust and reliable but did not reveal the elusive correlate of protection.
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Background
Malaria caused by Plasmodium falciparum infection 
remains a major cause of morbidity and mortality world-
wide. In 2015, 214 million clinical malaria cases resulted 
in an estimated 438,000 deaths, mostly in children and 
pregnant women in sub-Saharan Africa [1]. Over the past 
decades significant efforts have been made to develop a 
malaria vaccine but this process is hampered by the abil-
ity of Plasmodium species to evade and suppress the host 
immune response [2, 3] and by the incomplete under-
standing of how protective immunity to malaria develops 
[4–7].
Several vaccine candidates, targeting different stages 
of the parasite life cycle have been developed and shown 
varying degrees of success upon evaluation [8, 9]. The 
most advanced malaria vaccine candidate directed 
against P. falciparum is RTS,S/AS01 (GSK Vaccines). This 
vaccine targets the pre-erythrocytic stage of the para-
site and focuses on the circumsporozoite protein (CSP). 
It consists of 19 NANP amino acid repeat units followed 
by the complete C-terminal domain without the GPI 
anchor of the CSP fused to the hepatitis B surface anti-
gen (HBsAg) [10]. Efficacy trials have shown that over 
the first 18 months following three doses of RTS,S/AS01, 
malaria cases were reduced by almost half in children 
aged 5–17 months at the time of first vaccination and by 
27% in infants aged 6–12 weeks. At study end, four doses 
of RTS,S/AS01 reduced malaria cases by 39% over 4 years 
of follow-up in children, and by 27% over three years of 
follow-up in infants [11, 12]. In July 2015, the Committee 
for Medicinal Products for Human Use (CHMP) of the 
European Medicines Agency (EMA) has adopted a posi-
tive scientific opinion for the RTS,S/AS01 vaccine in chil-
dren aged 6 weeks to 17 months.
RTS,S/AS01 vaccination induces high IgG concen-
trations against the NANP repeat region of CSP and 
moderate to high CD4+ Th1 responses against flank-
ing region peptides [13–15]. Both responses are associ-
ated with protection, but an exact correlate of protection 
has not yet been defined. While some studies show no 
direct association between the anti-NANP IgG concen-
tration and protection against clinical disease [16, 17], 
others suggest that antibodies play a key role in RTS,S/
AS01-mediated protection [13, 18–22]. It has been dem-
onstrated that administration of human monoclonal anti-
bodies (mAbs, called MAL1C, MAL2A, MAL3B) derived 
from an RTS,S/AS01 vaccine recipient and directed 
against the NANP repeat region of CSP to immune defi-
cient mice with humanized livers was able to convey 
protection from infection with P. falciparum in a dose-
dependent manner [23].
RTS,S/AS01-induced antibodies are quantified with a 
validated ELISA that uses R32LR recombinant protein 
as a capture antigen [24]. There is evidence for the pro-
tective capacity of RTS,S/AS01-induced antibodies in 
humans, but the correlation between protection and anti-
body concentrations is far from being perfect. The dose-
dependent protection conveyed by RTS,S/AS01-induced 
mAbs in the humanized mouse model [23] encouraged 
us to investigate whether a correlation may exist between 
the protective capacity of RTS,S/AS01 vaccine-induced 
polyclonal antibodies and their content of MAL1C-like 
activity. Therefore a competition assay has been devel-
oped to measure MAL1C-like activity of polyclonal, vac-
cine-induced sera. Sera derived from participants in two 
RTS,S/AS01 trials were analysed with both the MAL1C-
competition ELISA and the validated R32LR ELISA. The 
results of both assays were compared and correlated 
with protection status against P. falciparum infection of 
these vaccine recipients following a sporozoite challenge 
2 weeks following last vaccine dose.
Methods
Serum samples
Serum samples from participants in the two clinical trials 
were analysed to evaluate the presence of both MAL1C-
type activity and R32LR-binding in the reference ELISA.
Study 1 (ClinicalTrials.gov Identifier: NCT01366534) 
evaluated whether administration of two investigational 
malaria vaccines (RTS,S/AS01B from GSK Vaccines and 
Ad35.CS.01, a replication deficient adenovirus type 35 
circumsporozoite malaria vaccine from Crucell) com-
bined in one immunization schedule increased protec-
tion against malaria infection as compared to protection 
induced by RTS,S/AS01B alone. A full report of the study 
has recently been published [25]. Sera from 46 study par-
ticipants analysed here were taken before the 1st vaccine 
administration (Day 0), 4 weeks after the 2nd dose (D56) 
and 3 weeks after the administration of the 3rd vaccine 
dose, immediately before controlled human malaria par-
asite infection (CHMI), through the bite of 5 P. falcipa-
rum-infected Anopheles stephensi mosquitoes (Day 77).
Study 2 (ClinicalTrials.gov Identifier: NCT01857869) 
evaluated safety, immunogenicity, and efficacy of RTS,S/
AS01B administered intramuscularly as standard doses 
at 0–1  month and a 1/5th standard dose at 7  months 
(delayed fractional dose group, 017) as compared to 
RTS,S/AS01B administered as three standard doses at 
monthly intervals (0, 1, 2 months group, 012) in healthy 
malaria-naïve volunteers aged 18–50 years. A full report 
of the study has recently been published [26]. Samples 
analysed in the present study were taken prior to vacci-
nation, 4 weeks after the second dose (D56) and 3 weeks 
after the 3rd dose (D217) prior to CHMI in the former 
group and prior to vaccination, prior to the 3rd dose 
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(D196), and 3  weeks after the 3rd dose (D217) prior to 
CHMI in the latter group.
Study samples were analysed in a blinded fashion. Fol-
lowing analysis, information was obtained about sam-
pling time and subject status (protected/unprotected). 
Protection is defined as absence of parasitaemia in blood 
samples 28 days post CHMI.
Negative control serum samples were obtained from 
healthy adults living in malaria non-endemic areas and 
considered as anti-CSP repeats antibody seronegative. 
Positive control samples were pools of post-vaccina-
tion serum samples, used in the R32LR ELISA. The low 
positive control (LPC) and high positive control (HPC) 
have an antibody content of 9.48 and 99.94 EU/ml, 
respectively.
Human monoclonal antibodies
Human monoclonal antibodies (mAb), MAL1C, 
MAL2A and MAL3B, were generated in 2008 in the 
Center for Vaccinology (Ghent, Belgium) using periph-
eral blood mononuclear cells (PBMC) from the indi-
vidual vaccinated with RTS,S/AS01 who showed the 
highest anti-R32LR antibody concentration one month 
after the 3rd vaccine dose (ClinicalTrials.gov Identifier: 
NCT00443131) [27]. Six days after injection of human 
PBMC in the spleens of conditioned SCID mice, the 
spleens were harvested and the cells, a large fraction 
of which were human B lymphocytes, were fused with 
K6H6/B5 heteromyeloma cells, and grown in hybridoma 
selection medium as described [28]. Hybridoma culture 
supernatants were tested for the presence of human anti-
R32LR antibodies and cultures producing anti-R32LR 
antibodies were selected, expanded and subcloned. The 
mAbs MAL1C, MAL2A and MAL3B are of the IgG1 
isotype and directed against the repeat region of circum-
sporozoite protein (CSP).
Biotin labelling of monoclonal antibody MAL1C
Biotin labelling of human monoclonal antibody MAL1C 
was performed using the EZ-Link™ Sulfo-NHS-LC-
Biotinylation Kit (Thermo Scientific) according to the 
manufacturers guidelines. Briefly, a 20-fold molar excess 
of Sulfo-NHS-LC-Biotin was added to MAL1C solu-
tion in phosphate buffer saline (PBS) and the reaction 
was incubated on ice for 2  h. After the reaction, excess 
biotin reagent was removed using a desalting column 
provided with the kit. The degree of biotin labelling was 
determined with the HABA (4′-hydroxyazobenzene-
2-carboxylic acid)/avidin solution provided with the 
kit and following the instruction manual. Biotinylated 
MAL1C (B-MAL1C) was diluted with PBS and aliquots 
were stored at −20 °C. Once thawed the B-MAL1C was 
stored at 4  °C. Specificity of the biotin labelled MAL1C 
was tested with the R32LR ELISA [24]. To examine the 
impact of biotinylation on the functional integrity of 
MAL1C, the antibody concentration was measured using 
both the standard R32LR ELISA (see below) and a human 
IgG ELISA Quantitation Set (Bethyl Laboratories, Mont-
gomery, TX, USA). The latter was performed following 
the manufacturer’s guidelines.
Capturing antigens in ELISA
R32LR protein is a recombinant repeat region of the P. 
falciparum circumsporozoite protein produced in AR58 
Escherichia coli strain, as already described [29]. His-
R32LR was constructed with six histidine residues at the 
N-terminus and produced in the BLR(DE3) E. coli strain 
as described in [24]. After purification, both antigens 
were kept in 0.2 M phosphate buffer, pH 6.5 and stored in 
aliquots at −80 °C.
R32LR ELISA
The R32LR ELISA was performed as described previ-
ously [24]. Briefly, antigen R32LR was coated onto a 
96-well polystyrene plates (F96, MaxiSorp, Nunc). After 
coating, plates were washed three times with phosphate-
buffered saline (PBS, pH 7.4) supplemented with 0.1% 
Tween-20 (v/v; Sigma, ref P1379). After blocking the 
plates with blocking buffer, consisting of PBS (pH 7.4) 
containing 0.1% Tween-20 (v/v) and 0.5% skimmed milk 
(Becton–Dickinson, ref 232100), for 2 h at room temper-
ature (RT) on an orbital shaker, serial dilutions of serum 
samples were added to the plates and incubated for 2 h at 
37 °C. The plates were washed and polyclonal rabbit anti-
human IgG/HRP was added. After a final washing step 
the chromogen substrate [3,3′,5,5′-tetramethylbenzidine 
solution (Sigma, ref T-0440)] was added and incubated 
for 15 min at RT on an orbital shaker. The reaction was 
stopped by the addition of 100 μl of 1 N sulphuric acid, 
before reading the assay plate at 450 nm in a microtiter 
plate reader. The titers were calculated from a standard 
curve with the software SoftmaxPro (using a four param-
eters equation) and expressed as EU/ml. The cut-off for 
the anti-CSP ELISA was 0.5 EU/ml.
Surface plasmon resonance
Surface plasmon resonance experiments were performed 
on a BIAcore T200 system (GE Healthcare). The interac-
tions between the CSP-derived peptides ([NANP]6 and 
R32LR) and the mAbs (MAL1C, MAL2A, MAL3B) were 
analysed on a CM5 chip. The mAbs were immobilized 
using the following procedure. Using a flow rate of 5 μl/
min the carboxylated dextran matrix was activated by a 
7-min injection of a solution containing 0.2  M  N-ethyl-
N′-(3-diethylamino) propyl carbodiimide (EDC) and 
0.05  M  N-hydroxysuccinimide (NHS). For the covalent 
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coupling, the mAbs were prepared at a concentration of 
10 μg/ml in coupling buffer (50 mM sodium acetate pH 
5.0) and were subsequently injected until about 2500 
resonance units (R.U.) was immobilized. The surface 
immobilization was then blocked by a 7-min injection 
of 1  M ethanolamine hydrochloride. The reference sur-
face was treated only with EDC, NHS, and ethanola-
mine. Data for the interaction between the CSP-derived 
peptides and the mAbs were collected in the format of a 
kinetic titration [30]. Sensorgrams for the CSP-derived 
peptides were collected at five different concentrations 
plus a 0 concentration (injection of running buffer) at a 
flow rate of 30 μl/min and a data collection rate of 10 Hz. 
Analyte injections were performed with association 
phases of 180  s and dissociation was allowed to occur 
for 600 s. Prior to data analysis, reference and zero con-
centration data were subtracted from the sensorgrams. 
For kinetic analysis, the data were analysed with a 1:1 
Langmuir binding model [30]. In the case of the mAb-
[NANP]6 interaction, fitting the data with the aforemen-
tioned model reports the affinity constant (KD) for a 1:1 
interaction. However, for the mAb-R32LR interaction, 
we believe that the mAb- R32LR interaction is the result 
of an avidity effect because of the relatively long repeat 
region in this CSP-derived protein. Hence, the affinity 
constant obtained from fitting the data with a 1:1 interac-
tion model is reported as apparent (KD,app).
MAL1C‑competition ELISA
MAL1C-like activity in polyclonal sera was measured as 
follows. His-R32LR was coated (100 μl/well of a solution 
of 0.5  μg/ml prepared in 0.05  M carbonate/bicarbonate 
buffer, pH 9.4-9.8) onto a 96-well polystyrene plate (F96, 
MaxiSorp, Nunc) for 14–16  h at 5  ±  3  °C. After coat-
ing, plates were washed 3 times with phosphate-buffered 
saline (PBS, pH 7.4) supplemented with 0.1% Tween-20 
(v/v; Sigma, ref P1379). Nonspecific binding sites were 
saturated with 200  μl/well of blocking buffer, consisting 
of PBS (pH 7.4) containing 0.1% Tween-20 (v/v) and 0.5% 
skimmed milk (Becton–Dickinson, ref 232100), for 2 h at 
room temperature (RT) on an orbital shaker. After block-
ing the plate was turned upside down to remove blocking 
buffer, and gently tapped down on clean blotting paper. 
Eight twofold dilutions of controls and samples were 
made in buffer containing a fixed amount of B-MAL1C. 
The determination of the optimal amount of B-MAL1C is 
described in “Results” section. These mixtures were then 
added to the plate (100 μl/well) and incubated for 2 h at 
37  °C. The plates were washed three times before per-
oxidase-conjugated streptavidin (Streptavidin-HRP, GE 
Healthcare Life Sciences, RPN4401) diluted in blocking 
buffer was added for 30 min incubation at RT. The deter-
mination of the optimal amount of Streptavididn-HRP 
is described in “Results” section. After another washing 
step, the chromogen substrate [3,3′,5,5′-tetramethylben-
zidine solution (Sigma, ref T-0440)] was added and incu-
bated for 15 min at RT on an orbital shaker. The reaction 
was stopped by the addition of 100  μl of 1  N sulphuric 
acid, before reading the assay plate at 450 nm in a micro-
titer plate reader. The signal obtained is inversely propor-
tional to the amount of MAL1C-like antibodies present in 
the samples (competition assay). The amount of antibody 
competing with MAL1C mAb for binding to the coated 
R32LR-His is quantified by comparison to a serum not 
containing anti-CSP antibodies. Results are expressed 
as the half maximal inhibitory concentration (IC50) that 
was calculated using the Softmax Pro software (Molecu-
lar Devices, Sunnyvale, CA, USA). Individual OD values 
of 8 dilutions of each sample are converted into % Inhibi-
tion (as compared to reference). A four-parameter logis-
tic curve is fitted for each sample.
The Inter-Assay stability was monitored by includ-
ing a low and high anti-CSP antibody-containing serum 
on each assay plate. The resulting IC50 of both controls 
were calculated as outlined above. Low and High anti-
CSP containing controls resulted in a mean IC50 value of 
11.80 and 27.14, respectively. The observed imprecision 
(%CV) for both controls were 10.99–16.92%.
In each plate the negative control (identical serum used 
as calculation reference) was used to evaluate the assay 
noise and therefore indirectly determine the ability of the 
assay to discriminate positive results (MAL1C-like anti-
bodies containing samples) from negative sera. Based on 
37 observations a technical assay threshold could be set 
at an IC50 value of 9.92.
Statistical analysis
Comparisons between groups (e.g. protected versus 
unprotected) were done with Mann–Whitney U test. The 
correlation between antibody data measured with R32LR 
ELISA and MAL1C-competition ELISA were examined 
using linear regression and Pearson’s correlation analysis.
Results
Biotin‑labelled MAL1C retains antigen‑binding quality
Biotin labelling of MAL1C was performed using the EZ-
Link™ Sulfo-NHS-LC-Biotinylation Kit (Thermo Scien-
tific). Using the HABA assay for measuring the level of 
biotin incorporation that is provided with the EZ-Link™ 
Sulfo-NHS-LC-Biotinylation Kit the degree of biotin 
incorporation was determined to be 4:1 (mmol of bio-
tin per mmol of protein). This is within the range that 
can be achieved with this kit. To examine whether the 
biotinylation procedure had altered structural and/or 
antigen-binding properties of MAL1C, the IgG content 
and the antigen-binding capacity of the B-MAL1C were 
Page 5 of 11Radin et al. Malar J  (2016) 15:543 
measured with the IgG ELISA Quantitation Set and the 
standard R32LR ELISA, respectively. The antibody con-
tent of the B-MAL1C was 3.54  mg/ml with the R32LR 
assay and 3.73 mg/ml with the IgG ELISA, showing that 
the labelling procedure had not detectably altered the 
mAb.
Development of the MAL1C‑competition ELISA
Plates were coated with the capturing antigen His-
R32LR as described in “Methods” section. Optimal 
dilutions of B-MAL1C and streptavidin-HRP were 
determined using a checkerboard titration set-up. The 
streptavidin-HRP conjugate dilutions ranged between 
1/16,000 and 1/1,024,000 and B-MAL1C dilutions 
between 1/12,500 and 1/12,800,000. A prototypic 
sigmoidal curve was obtained at a streptavidin-HRP 
conjugate concentration of 1/16,000 (Fig.  1a). This 
dilution was, therefore, used in further experiments. 
An optimal B-MAL1C dilution was chosen in the 
range that produced between 50 and 100% of the 
maximal absorbance (A450) value, which was between 
1/50,000 (100%) and 1/400,000 (50%). To find the most 
discriminating assay condition, dilutions of B-MAL1C 
(1/50,000, 1/100,000, 1/200,000 and 1/400,000) were 
tested in a competition ELISA set-up with a low posi-
tive control (LPC) and high positive control (HPC) 
serum (Fig.  1b) and non-labelled monoclonal anti-
bodies MAL1C, MAL2A, MAL3B (5  µg/ml starting 
dilution) (Fig.  1c). Serial twofold dilutions HPC, LPC 
and mAbs were examined in an inhibition set-up. The 
maximum inhibition and most discriminative results 
HPC and LPC were observed in the least diluted sam-
ple (starting dilution 1/5) and at a 1/400,000 dilution 
of B-MAL1C. At this dilution of B-MAL1C also maxi-
mal inhibitory effects of 5  µg/ml of the three mAbs 
were noted (Fig. 1c). Therefore, a 1/400,000 dilution of 
Fig. 1 Development of the MAL1C‑competition ELISA. Optimal dilutions of B‑MAL1C and streptavidin‑HRP were defined using a checkerboard 
titration experiment (a). At a 1/16,000 dilution of streptavidin‑HRP a sigmoidal curve was observed; this dilution was used for further experiments. 
B‑MAL1C dilutions in the range between the maximal absorbance (plateau observed at 1/50,000) and half max (max/2 observed at 1/400,000) were 
explored in an inhibition set up using defined sera with high and low antibody content in R32LR ELISA assay (b) and the three monoclonal antibod‑
ies, MAL1C, MAL2A and MAL3B (c). The data shown in panels b and c were obtained with the highest serum concentrations (starting dilution 1/5) 
and with mAb concentrations of 5 µg/ml
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B-MAL1C was used in further testing and assay evalu-
ation. The degree with which polyclonal sera or mAbs 
inhibited the interaction of B-MAL1C with the R32LR 
capturing antigen was expressed as % inhibition rela-
tive to a non-inhibiting control sample as described in 
“Methods” section.
Competition ELISA with MAL1C, MAL2A and MAL3B
Figure  1c further demonstrates that the three mAbs 
(MAL1C, MAL2A, MAL3B) differently inhibit the inter-
action of B-MAL1C (at optimal dilution of 1/400,000) 
with the R32LR capturing antigen. MAL3B displays 
the strongest inhibition not only when mixed with the 
B-MAL1C diluted at 1/400,000 but also when mixed 
with higher amounts of B-MAL1C (1/50,000–1/200,000). 
MAL1C behaves largely like MAL3B but MAL2A exhib-
ited much lower inhibitory activity than the two other 
mAbs.
To explore these differences further, the binding inter-
actions between the mAbs (MAL1C, MAL2A, MAL3B) 
and the CSP-derived proteins ([NANP]6 and R32LR) 
were analysed via surface plasmon resonance (SPR). In 
the experimental set-up, the mAbs were coated onto the 
sensor surface, whereas the CSP-derived peptides were 
selected as analytes. First, the binding of the three mAbs 
to (NANP)6 was evaluated. As can be seen from Fig.  2 
and Additional file  1: Table  S1, the three mAbs display 
no difference in (NANP)6-binding behaviour as MAL1C, 
MAL2A, and MAL3B possess similar affinities in the 
nM range. However, upon evaluation of mAb binding 
Fig. 2 Interactions between the three mAbs (MAL1C, MAL2A, and MAL3B) and the CSP‑derived peptides as measured by SPR. The data for the 
mAb:CSP‑peptide interaction were measured in the format of a kinetic titration [30], with mAb as the ligand (i.e., coated onto the sensor surface) 
and either (NANP)6 (a) and R32LR (b) as the analyte. In both panels, the top graphs display the sensorgrams (black traces) and the fit to the data with 
a 1:1 Langmuir binding model (red traces). The residuals of the fit are shown in the bottom graph. The (apparent) affinity constants for the interac‑
tions and the chi2 of the fit are also shown for convenience. KD dissociation constant, KD, app apparent dissociation constant, s seconds, RU resonance 
units
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to R32LR, a significant difference could be observed 
between MAL1C and MAL3B on one hand, and MAL2A 
on the other. While MAL1C and MAL3B interact with 
R32LR with very comparable apparent affinities, MAL2A 
binding to R32LR is fivefold weaker (Fig.  2 and Addi-
tional file 1: Table S1).
Correlation between MAL1C‑competition ELISA and R32LR 
ELISA
Antibody concentrations were measured in sera from 46 
participants from study 1 obtained at three points in time 
(before vaccination, 4  weeks after the 2nd dose (D56) 
and 3 weeks after the administration of the 3rd vaccine 
dose). Similarly, antibody contents were also measured in 
sera from 46 participants from study 2. The samples were 
taken prior to vaccination in all participants and 4 weeks 
after the second dose (D56) and 21  days after the 3rd 
dose (D217) in one study group and prior to the 3rd dose 
(D196, or 168 days after the 2nd dose), and 21 days after 
the 3rd dose (D217) in the other group (Additional file 2: 
Figure S1). All sera were analysed with both the R32LR 
ELISA and the MAL1C-competition ELISA. In the lat-
ter, optimal reagent conditions (1/16,000 streptavidin-
HRP conjugate dilution and 1/400,000 B-MAL1 dilution) 
were applied. Prior to vaccination no antibodies could be 
detected with either method.
Using the assay developed herein, MAL1C-like anti-
bodies were detected in most post-vaccination sera. 
Figure  3 shows an overall good correlation between 
the results obtained in both assays. The Pearson cor-
relation coefficients were 0.705 (P  <  0.0001) and 0.5461 
(P < 0.0001) in the study 1 and 2 sample sets, respectively.
The antibody levels measured with both assays at differ-
ent time points, elicited by varying vaccination schemes 
in both studies allowed a comparison of the MAL1C-like 
antibody profiles with those generated with the anti-CS 
ELISA. Figure  4 shows that both assays generate data 
displaying similar patterns and that the measurement 
of MAL1C-like antibodies does not provide additional 
information. Antibody levels measured after three doses 
of RTS,S/AS01were not significantly higher than those 
measured after two doses. Post dose 3, different vaccine 
regimens in study 1 and administration schemes in study 
2 had no significant impact on antibody levels, irrespec-
tive of the assay used.
Finally, it was examined whether the antibody content 
measured with the MAL1C-competition ELISA would 
reveal a better association with protection from infection 
than that measured with the R32LR ELISA. In samples 
from both studies and irrespective of the assay method 
used, no association was observed between the antibody 
content and the protection status of the vaccine recipi-
ents (Fig.  5). The MAL1C-competition ELISA, which 
quantifies only the MAL1C-like antibodies in a poly-
clonal serum sample, provides no additional information 
about the protective capacity of polyclonal sera.
Discussion
A competitive ELISA was developed to measure in 
sera from RTS,S/AS01 vaccine recipients the fraction 
of polyclonal antibodies that compete with MAL1C, a 
human monoclonal antibody, derived from an RTS,S/
AS01 vaccinated volunteer, directed against the central 
repeat region of CSP. A survey of 276 sera derived from 
92 participants in two clinical trials that examined the 
protective efficacy of the RTS,S/AS01 candidate vaccine, 
demonstrated that most, if not all, of the polyclonal anti-
bodies present in sera of study participants behaved like 
the human monoclonal antibody MAL1C, suggesting 
they compete for the same binding site(s) on the captur-
ing antigen, R32LR.
Fig. 3 Correlation between R32LR ELISA and MAL1C‑competition 
ELISA. Sera from participants in study 1 (panel A) and study 2 (panel 
B) taken after the second and third vaccine doses (immediately prior 
to mosquito bite challenge) were analysed with the standard R32LR 
ELISA and the MAL1C‑competition ELISA. Results obtained with 
both assays are plotted and correlation is calculated with Pearson’s 
correlation
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Polyclonal antibodies elicited by vaccination with 
RTS,S/AS01 and directed against the central repeat 
region of the CSP are able to protect vaccine recipients 
against challenges with infected mosquitoes [13, 31–33]. 
Administration of human mAbs directed to the cen-
tral repeat region of CSP (MAL1C, MAL2A, MAL3B), 
derived from one RTS,S/AS01 vaccine recipient, was 
also shown to convey protection against P. falciparum 
infection in immune deficient mice with human liver 
tissue [23]. Although no precise antibody threshold has 
been defined above which protection from infection is 
secured, some association between anti-CS concentra-
tion and protection from infection has been observed in 
man [13, 18–22] and mice [23]. However the overlap in 
antibody concentrations of protected and non-protected 
individuals as measured with the standard R32LR ELISA 
is considerable. The use of the MAL1C-competition 
ELISA compared to the R32LR ELISA does not provide 
additional information or discriminatory power.
The protective role of antibodies directed against the 
central repeat region of CSP is well established. However 
the inability to define a precise correlate of protection 
and the large overlap of anti-CS concentrations between 
protected and unprotected populations suggest that 
other factors may be involved. Apart from the actions of 
cells from the innate (NK, NKT) and adaptive immune 
Fig. 4 Comparison of antibody concentrations in sera from different time points and treatment groups. In both studies sera were obtained after 
the second (PD2) and third (PD3) vaccine dose and antibody concentrations were measured with R32LR and MAL1C‑competition ELISA. In study 
1 results obtained in the subjects receiving three doses of RTS,S/AS01 (3xRTS,S/AS01) were compared with those generated in subjects vaccinated 
with one dose of Ad35.CS.01 followed by two doses of RTS,S/AS01. In study 2, subjects vaccinated with three standard doses of RTS,S/AS01 given 
with monthly intervals at month 0, 1 and 2 (012) were compared with subjects given a standard dose at months 0 and 1 and 1/5 th of the standard 
dose at month 5 (017). No significant differences were observed between the study groups or between 2 and 3 vaccine doses
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system (CD4, CD8), also less explored antibody qualities 
such as affinity/avidity or antibody specificities that are 
not examined with the R32LR ELISA assay may contrib-
ute to protection.
Olotu et  al. [34] have examined the avidity of anti-
circumsporozoite antibodies, as measured using an elu-
tion ELISA method, in RTS,S/AS01E-vaccinated children 
residing in malaria endemic countries. In this survey 
no association between antibody avidity and protection 
from clinical malaria has been observed.
The different behaviour of the three mAbs (MAL1C, 
MAL2A and MAL3B) in the MAL1C-competition 
ELISA (Fig.  1b) led to study their binding interactions 
with the CSP-derived peptides ([NANP]6 and R32LR) 
via surface plasmon resonance (SPR). While the three 
mAbs showed a similar (NANP)6-binding behaviour, 
MAL2A bound fivefold weaker to R32LR than MAL1C 
and MAL3B, which displayed very comparable apparent 
affinities. Despite these observed differences in SPR and 
competition ELISA, the three mAbs display an equal pro-
tective capacity in the humanized uPA-SCID challenge 
model [23]. All three mAbs are extremely good binders 
of CSP with apparent picomolar affinities, which explains 
the in vivo protective effect of the mAbs when adminis-
tered separately to mice with human livers at a dose of 
400 µg/animal. However, when placed in direct competi-
tion to each other, differences can be observed between 
the three mAbs. Indeed, MAL1C and MAL3B have bet-
ter apparent affinities than MAL2A, which is why they 
score better in an inhibition assay.
The ELISA assays employed here only detect antibod-
ies recognizing the central repeat region of CSP and do 
not provide information on antibodies directed against 
the carboxy-terminal part of the RTS,S/AS01 vaccine 
antigen. Data about the amount of such antibodies that 
are induced by RTS,S/AS01 vaccination and their possi-
ble role in protection is scarce. In study 2, antibody titers 
against the C-terminus were shown not to be associated 
Fig. 5 Correlation between protection from infection and antibody content, measured with R32LR and MAL1C‑competition ELISA. Antibody 
concentrations in the sera obtained immediately before challenge with infected mosquito’s from participants at the study 1 (n = 46) and study 
2 (n = 46) studies were measured with the R32LR ELISA and MAL1C‑competition ELISA. Antibody levels in protected and non‑protected vaccine 
recipients were compared and no significant differences were observed irrespective of the assay used
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with protection [26]. Sera from malaria-naïve human 
volunteers infected with sporozoites under chloroquine 
prophylaxis (CPS vaccination) have protective qualities 
despite their low levels of antibodies directed against the 
central repeat region of CSP [35]. Antibodies that remain 
undetected with the R32LR ELISA may be responsible 
for this protection and deserve further exploration.
Conclusion
A competition ELISA to measure MAL1C-like antibod-
ies in polyclonal sera from RTS,S/AS01 vaccine recipi-
ents has been developed and showed that MAL1C-like 
antibodies that recognize the same epitope as the mAb 
MAL1C are induced by RTS,S/AS01 vaccination. An 
excellent correlation was observed between the results 
generated with the MAL1C-competition ELISA and 
those generated with the validated standard ELISA. In 
contrast to the findings in mice where protection from 
infection was directly associated with circulating MAL1C 
mAb concentrations, no such association was observed 
between, MAL1C-like antibody concentrations detected 
in sera from RTS,S/AS01 vaccine recipients and protec-
tion from infection following infected mosquito bites. 
These results warrant further in depth analysis of the 
composition of polyclonal sera from RTS,S/AS01 vaccine 
recipients and further assessment of the binding qualities 
and function of these antibodies.
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